Department of Biochemistry, Chhatrapati Shahu Ji Maharaj Medical University, Lucknow, Uttar Pradesh, India.
Singapore Med J. 2010 Feb;51(2):110-5.
Chronic myeloid leukaemia (CML) is a myeloproliferative disorder of the haematopoietic cell. Free radicals can be important causative agents of a number of human diseases, including cancer and leukaemia. Thus, antioxidants, which control the oxidative stress state, represent a major line of defense for regulating the overall true state of health. The relationship between non-enzymatic antioxidant status and the levels of well-known markers of oxidative stress that are measured as lipid peroxides reflects better health indices. The aim of this study was to evaluate the plasma levels of lipid peroxidation products and non-enzymatic antioxidant status as indices of oxidative stress, disease progression and early responses to chemotherapeutic agents in chronic myeloid leukaemia patients.
The study included 128 CML patients and 50 age- and gender-matched healthy control volunteers. Indices of oxidative stress were evaluated as lipid peroxidation and non-enzymatic antioxidant status using the spectrophotometric method.
There was a significant increase in the plasma levels of lipid peroxidation products in CML patients as compared to the healthy volunteers. The plasma levels of lipid peroxidation products continued to rise significantly as the disease progressed. The non-enzymatic antioxidant status was found to be significantly decreased in CML patients as compared to the healthy participants. The plasma levels of non-enzymatic antioxidant status continued to decrease significantly during the disease progression.
It can be concluded that plasma lipid peroxidation and non-enzymatic antioxidant status reflect oxidative stress in CML patients, and may be used as indices for oxidative stress, disease progression and early responses to different therapeutic modalities.
慢性髓性白血病（CML）是造血细胞的骨髓增生性疾病。自由基可以是许多人类疾病的重要致病因素，包括癌症和白血病。因此，控制氧化应激状态的抗氧化剂是调节整体健康真实状态的主要防御线。非酶抗氧化状态与作为脂质过氧化物测量的氧化应激的已知标志物水平之间的关系更好地反映了健康指标。本研究旨在评估慢性髓性白血病患者的血浆脂质过氧化产物水平和非酶抗氧化状态作为氧化应激、疾病进展和对化疗药物早期反应的指标。
该研究包括 128 例 CML 患者和 50 名年龄和性别匹配的健康对照志愿者。使用分光光度法评估氧化应激的指标，如脂质过氧化和非酶抗氧化状态。
与健康志愿者相比，CML 患者的血浆脂质过氧化产物水平显着升高。随着疾病的进展，脂质过氧化产物的血浆水平继续显着升高。与健康参与者相比，CML 患者的非酶抗氧化状态显着降低。在疾病进展过程中，非酶抗氧化状态的血浆水平继续显着降低。
可以得出结论，血浆脂质过氧化和非酶抗氧化状态反映了 CML 患者的氧化应激，并且可以作为氧化应激、疾病进展和对不同治疗方式的早期反应的指标。
